Lumida
/ACAD
⌘K
ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

ACAD
$27.83USD+0.32%+0.09 today

MARKET CAP

4.8B

P/E (TTM)

12.1x

FWD P/E

DAY RANGE

$28 – $28

52W RANGE

$20
$31

AI Summary

Stalk
Sell NowMedium

ACAD is forming a series of lower highs and lower lows beneath falling EMAs, confirming a Medium-Term bearish bias within the broader uptrend. The recent rally into the 9/20 EMA zone is facing resistance, offering a tactical opportunity to sell now on the bounce. Short-Term execution favors selling into dynamic resistance, while the 200 DMA uptrend supports the longer-term bull case but remains overshadowed by current distribution.

  • Q2 2026 revenue $308M (+17% YoY), driven by Debut & New Placid
  • Debut net sales $125M (+30% YoY); New Placid $183M (+10% YoY)
  • Earnings yield at ~0.07% signals costly entry point
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$484.1M$517.2M$726.4M$957.8M$1.1B
YoY %+9.6%+6.8%+40.4%+31.8%+11.9%
P / Sales7.7x5.1x7.0x3.2x4.2x
EV / Sales7.8x5.2x7.1x3.3x4.4x
Gross Profit, Adj.$465.0M$507.1M$684.8M$876.0M$982.5M
YoY %+7.8%+9.0%+35.1%+27.9%+12.2%
Margin %96.0%98.0%94.3%91.5%91.7%
EV / Gross Profit8.1x5.3x7.6x3.6x4.8x
EBITDA, Adj.$-167.1M$-221.6M$-67.8M$100.2M$116.6M
YoY %+41.1%-32.6%+69.4%+247.7%+16.4%
Margin %-34.5%-42.8%-9.3%10.5%10.9%
EV / EBITDA-22.5x-12.2x-76.4x31.8x40.3x
EBIT$-170.4M$-223.6M$-73.4M$84.3M$104.8M
YoY %+40.5%-31.2%+67.2%+214.9%+24.4%
Margin %-35.2%-43.2%-10.1%8.8%9.8%
EV / EBIT-22.0x-12.1x-70.6x37.8x44.8x
Net Income$-167.9M$-216.0M$-61.3M$226.5M$391.0M
YoY %+40.4%-28.7%+71.6%+469.5%+72.7%
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (GAAP)-$1.05-$1.34-$0.37$1.36$2.30
YoY %+41.3%-27.6%+72.4%+467.6%+69.1%